Total Payments
$10,598
2024 Payments
$4,899
Companies
30
Transactions
546
Medicare Patients
1,410
Medicare Billing
$71,278
Payment Breakdown by Category
Food & Beverage$9,060 (85.5%)
Other$1,020 (9.6%)
Education$518.50 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,060 | 537 | 85.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,020 | 1 | 9.6% |
| Education | $518.50 | 8 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,703 | 208 | $0 (2024) |
| Incyte Corporation | $1,689 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $942.31 | 48 | $0 (2024) |
| GENZYME CORPORATION | $758.74 | 38 | $0 (2024) |
| PFIZER INC. | $527.06 | 38 | $0 (2024) |
| LEO Pharma Inc. | $495.91 | 21 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $441.76 | 19 | $0 (2024) |
| Dermavant Sciences, Inc. | $439.14 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $421.77 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $405.27 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,899 | 209 | Incyte Corporation ($1,401) |
| 2023 | $3,300 | 181 | ABBVIE INC. ($783.01) |
| 2022 | $1,923 | 125 | ABBVIE INC. ($547.63) |
| 2021 | $475.56 | 31 | AbbVie Inc. ($168.48) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 22 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/20/2021 | Novartis Pharmaceuticals Corporation | XOLAIR (Biological) | Food and Beverage | In-kind items and services | $8.68 | General |
| Category: RESPIRATORY | ||||||
| 07/06/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: IMMUNOLOGY | ||||||
| 07/02/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.03 | General |
| Category: IMMUNOLOGY | ||||||
| 06/10/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $5.51 | General |
| 05/27/2021 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $28.16 | General |
| 05/25/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $15.79 | General |
| 05/18/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: DERMATOLOGY | ||||||
| 05/14/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: IMMUNOLOGY | ||||||
| 05/07/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $6.42 | General |
| 04/15/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.63 | General |
| Category: IMMUNOLOGY | ||||||
| 04/09/2021 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $16.27 | General |
| 04/08/2021 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $29.72 | General |
| 03/16/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological), XOLAIR | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: IMMUNOLOGY | ||||||
| 03/09/2021 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Immunology | ||||||
| 02/10/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: IMMUNOLOGY | ||||||
| 02/10/2021 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Immunology | ||||||
| 02/08/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological), COSENTYX | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: IMMUNOLOGY | ||||||
| 01/29/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $10.98 | General |
| Category: IMMUNOLOGY | ||||||
| 01/28/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: DERMATOLOGY | ||||||
| 01/21/2021 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: IMMUNOLOGY | ||||||
| 01/20/2021 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 461 | 863 | $77,996 | $23,865 |
| 2022 | 9 | 342 | 558 | $55,783 | $16,348 |
| 2021 | 10 | 307 | 467 | $47,627 | $14,352 |
| 2020 | 9 | 300 | 479 | $50,797 | $16,713 |
Total Patients
1,410
Total Services
2,367
Medicare Billing
$71,278
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 109 | 134 | $20,773 | $6,152 | 29.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 71 | 76 | $13,231 | $3,984 | 30.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 88 | 111 | $12,364 | $3,449 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 43 | $9,519 | $2,956 | 31.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $7,111 | $2,165 | 30.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 23 | 31 | $5,891 | $1,939 | 32.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 58 | 377 | $4,072 | $1,542 | 37.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 27 | 32 | $3,079 | $1,069 | 34.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 18 | 22 | $1,955 | $607.78 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 81 | 101 | $15,678 | $4,697 | 30.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 61 | 62 | $10,794 | $3,364 | 31.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 62 | 76 | $8,466 | $2,443 | 28.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $6,340 | $1,784 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 25 | $5,496 | $1,412 | 25.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 16 | 20 | $3,801 | $1,032 | 27.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 44 | 215 | $2,322 | $827.36 | 35.6% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $1,738 | $568.46 | 32.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $1,149 | $220.59 | 19.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 73 | 81 | $12,622 | $4,075 | 32.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 45 | 48 | $8,361 | $2,532 | 30.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 51 | 60 | $6,686 | $1,652 | 24.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 23 | 27 | $5,133 | $1,542 | 30.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 25 | 25 | $4,798 | $1,338 | 27.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 14 | $3,100 | $926.48 | 29.9% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 17 | 21 | $1,867 | $687.78 | 36.8% |
About Sherri Howard, PA
Sherri Howard, PA is a Physician Assistant healthcare provider based in Bexley, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1689927485.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sherri Howard, PA has received a total of $10,598 in payments from pharmaceutical and medical device companies, with $4,899 received in 2024. These payments were reported across 546 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($9,060).
As a Medicare-enrolled provider, Howard has provided services to 1,410 Medicare beneficiaries, totaling 2,367 services with total Medicare billing of $71,278. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Bexley, OH
- Active Since 10/18/2012
- Last Updated 09/11/2018
- Taxonomy Code 363A00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689927485
Products in Payments
- OPZELURA (Drug) $1,689
- RINVOQ (Biological) $1,502
- DUPIXENT (Biological) $1,062
- SKYRIZI (Biological) $1,028
- TREMFYA (Drug) $864.37
- VTAMA (Drug) $439.14
- ADBRY (Biological) $428.77
- TALTZ (Drug) $404.95
- Sotyktu (Drug) $391.85
- EUCRISA (Drug) $332.98
- CIBINQO (Drug) $194.08
- ILUMYA (Biological) $168.96
- COSENTYX (Drug) $145.74
- HUMIRA (Biological) $122.66
- Cimzia (Drug) $122.14
- Bimzelx (Biological) $108.41
- COSENTYX (Biological) $103.80
- REMICADE (Biological) $77.94
- Zoryve (Drug) $69.65
- YCANTH (Drug) $61.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.